Drugs / Silmitasertib
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05817708 | Nov 2022 → Mar 2023 | COVID-19 | Senhwa Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03897036 | Apr 2019 → Jan 2024 | basal cell carcinoma | Senhwa Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01199718 | Sep 2010 → Jun 2011 | plasma cell myeloma | Cylene Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1 | NCT00891280 | Feb 2009 → Dec 2011 | Castleman disease, inflammatory breast carcinoma, plasma cell myeloma | Cylene Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06541262 | Oct 2024 → Nov 2030 expected | Ewing sarcoma, liposarcoma, neuroblastoma, osteosarcoma +1 | Milton S. Hershey Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03904862 | Jul 2019 → Aug 2025 | childhood medulloblastoma | Pediatric Brain Tumor Consortium | Terminated | No outcome recorded |
| Phase 1/2 | NCT02128282 | Jun 2014 → Nov 2020 | cholangiocarcinoma | Senhwa Biosciences, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06202521 | Mar 2024 → Apr 2025 | COVID-19, influenza, pneumonia | Senhwa Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04663737 | Nov 2020 → Aug 2021 | COVID-19 | Senhwa Biosciences, Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03571438 | Oct 2017 → Sep 2022 | kidney cancer | University Hospital, Grenoble | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04668209 Comparator | Jan 2021 → Jun 2022 | Coronaviridae infectious disease | University of Arizona | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Silmitasertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04663737 ↗ |
| Known as | CX 4945 | “This is a multi center, Phase I, Phase II and surgical study of the CX-4945 drug (silmitasertib sodium) for patients with recurrent SHH (Sonic Hedgehog) medulloblastoma” NCT03904862 ↗ |
| Known as | CX-4945 (SILMITASERTIB) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1230165 ↗ |
| Known as | CX-4945 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL1230165 ↗ |
| Known as | SILMITASERTIB (CX-4945) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1230165 ↗ |
| Action | Inhibit | “CX-4945 has demonstrated potent inhibition of CK2 enzymatic activity.” NCT00891280 ↗1“Casein kinase II alpha inhibitor” CHEMBL1230165 ↗ |
| Modality | Small molecule | “tetracyclic, small molecule carboxylate acid salt” NCT02128282 ↗ |
| Route | Oral | “CX-4945 Capsules, Oral” NCT00891280 ↗ |
| Target | CSNK2A1 | “Casein kinase II alpha inhibitor” CHEMBL1230165 ↗ |